Summary
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study
assessing the efficacy and safety of Dato-DXd compared with ICC in participants with
locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1
inhibitor therapy.